Penny Heaton, MD
BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE, CAMBRIDGE, MA
From Molecule to Patient: A Global Health Perspective
THURSDAY, MARCH 14, 2019
9:00 AM – 10:00 AM
ASCPT welcomes Penny Heaton, MD as a State of the Art speaker. She has been a tireless advocate for combating inequities in health for over twenty years, with a passion for finding new and effective interventions against diseases affecting the world’s poorest people. Dr. Heaton’s career journey as a pediatric infectious disease physician spans from the Centers for Disease Control and Prevention to the pharmaceutical industry before joining the Bill & Melinda Gates Foundation in 2013 to lead the vaccine development team. Dr. Heaton recognized the need to disrupt global health by applying cutting-edge science and technology to combat age-old diseases in the world’s poorest populations. Now, she is charged with leading the Bill & Melinda Gates Medical Research Institute (Gates MRI)—a nonprofit biotech organization focused on thinking big, exploring novel ideas, collaborating across disciplines, and being fearless in its approach to scientific inquiry in ways that aren’t always possible in the private sector or in academic research labs. The institute’s focus is translational medicine, with the ambitious goals of eradicating malaria, accelerating the end of the tuberculosis epidemic, and ending diarrheal deaths in children.
James (Jay) Bradner, MD
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, CAMBRIDGE, MA
A New Science of Therapeutics for Undruggable Targets
FRIDAY, MARCH 15, 2019
9:00 AM – 10:00 AM
James (Jay) Bradner, MD President of the Novartis Institutes for BioMedical Research (NIBR), is welcomed as a State of the Art speaker. He is a member of the Executive Committee of Novartis.
Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States. Dr. Bradner is a co-founder of five biotechnology companies and has authored more than 200 scientific publications and 30 US patent applications. Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School. He completed his residency in medicine at Brigham and Women's Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.
Robert S. Langer, Jr., ScD
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MA
From Molecule to Patient: A Biotech Perspective
FRIDAY, MARCH 15, 2019
1:00 PM – 2:00 PM
ASCPT welcomes Robert S. Langer, Jr., ScD, as a State of Art speaker. He is one of 13 Institute Professors at MIT (an Institute Professor is the highest honor awarded to a faculty member). His h-index of 259 is the highest of any engineer in history. He has over 1,300 issued and pending patents which have been licensed or sublicensed to over 350 companies. He served as Chairman of the US Food and Drug Administration’s SCIENCE BOARD (highest advisory board) from 1999-2002. Dr. Langer is one of a very few individuals elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors. He is one of four living individuals to receive both the US National Medal of Science and the US National Medal of Technology and Innovation. In 2015, Dr. Langer received the Queen Elizabeth Prize for Engineering. He has also received the Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, Kyoto Prize, Breakthrough Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 33 honorary doctorates, including honorary degrees from Harvard and Yale.